Moneycontrol Be a Pro
Get App
Last Updated : Jun 14, 2019 10:42 AM IST | Source:

Dr Reddys Labs slips 2% on agreement to sell neurology branded products

Dr Reddy's Labs will commercialise these products through its wholly owned subsidiary, Promius Pharma, LLC.

Moneycontrol News @moneycontrolcom
  • bselive
  • nselive
Todays L/H

Dr Reddy's Laboratories shares fell 1.7 percent intraday on June 14 despite company entered into a definitive agreement to sell its neurology branded products.

"We have entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which we would sell US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg," the drug maker said in its filing.

The company will commercialise these products through its wholly owned subsidiary, Promius Pharma, LLC, it added.


Under the agreement, Dr Reddy's said it would receive $70 million as upfront consideration, $40.5 million in near term milestones and additional financial considerations including, existing contractual obligation and inventory.

Subsequently, it will receive sales-based royalties on a quarterly basis, the company added.

"Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large but discrete segments of patients suffering from episodic migraine who need options other than their current therapies," said Anil Namboodiripad, Senior Vice President, Proprietary Products and Head, Promius Pharma.

The stock was quoting at Rs 2,549.00, down Rs 37.15, or 1.44 percent on the BSE at 10:18 hours IST.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Jun 14, 2019 10:42 am
Follow us on
Available On